Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. is a world-class biotechnology leader co-founded and led by CEO Leonard Schleifer and President/Chief Scientific Officer George Yancopoulos. The company’s mission is to "turn science into medicine," utilizing its proprietary VelociSuite technology to rapidly discover and develop high-impact therapies for eye diseases, cancer, and rare disorders. Regeneron holds a dominant market position with its blockbuster drugs EYLEA HD and DUPIXENT. Regeneron Pharmaceuticals, Inc. stock is a cornerstone of the biotech sector, representing a rare combination of massive cash flow from established products and a high-potential research pipeline.

The company’s business operations in late 2025 are focused on the "DUPIXENT Expansion" into new indications like COPD, which is expected to drive multi-billion dollar incremental growth. In 2025, Regeneron reported steady financial performance, with EYLEA HD successfully defending its market share against biosimilar threats through its superior dosing profile. The company’s future strategy is anchored by "The Regeneron Genetics Center," one of the world’s largest human genetics research programs, which identifies novel drug targets for a wide range of diseases. Future plans also include a deeper push into gene editing and cell therapy through strategic collaborations. Regeneron’s competitive moat is its unrivaled R&D efficiency, having developed nearly all its commercial products in-house, which leads to superior margins and lower risk compared to peers who rely on M&A.

Regeneron is listed on the Nasdaq under the ticker REGN stock. It is a favorite among institutional investors who seek "innovation with a safety net," given the company’s $78 billion market cap and strong return on equity. Market participants and biotech analysts track the REGN stock price as a primary indicator of the health of the high-end drug manufacturing market. By December 2025, Regeneron continues to lead the industry through scientific excellence and a disciplined approach to shareholder returns, including an attractive valuation relative to its forward earnings growth.